SEC EDGARSEP 81 min read$RGEN

Loeillot Olivier sold $504K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 3,035 shares of REPLIGEN CORP (RGEN) at $165.90 ($0.50M total) on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Loeillot Olivier

Published Sep 8, 2026, 8:13 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 8, 2026, 8:29 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$RGEN

Bearish

medium confidence

Mentioned

$RGEN

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$RGENBearishLow

Why it matters

The CEO's sale reduces his ownership, which may be interpreted as a negative signal, but the modest amount limits market reaction.

Market read

Primary disclosure of a CEO insider sale; modest size suggests limited trading impact but warrants monitoring.

What to watch

Potential 10b5‑1 plan execution and any upcoming earnings or clinical trial news could offset the sale impact.

Relevance 4/10Novelty 5/10Timing: post‑market filing on Sep 4 2026

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RGENBearishMedium confidence

Context

CEO Loeillot Olivier sold 3,035 shares of Repligen at $165.90 each, reducing his stake to 48,369 shares.

Expected impact

Possible modest downside of 1-2% over the next few days.

Evidence & confidence

The sale size (~$0.5M) is modest for a mid-cap, but CEO involvement adds weight; market may react negatively.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

Regional

Limited to U.S. investors tracking Repligen.

Global

Low; the filing does not affect broader markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

Company
Repligen Corp.
Biopharmaceutical company (ticker RGEN).
Person
Loeillot Olivier
Chief Executive Officer of Repligen.

Read at source ← All news

SEP 4

$BLFSMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min

SEP 4

$RGENHighAI 9/10

What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share

Repligen (RGEN) filed an amended Form S-4 to register shares for its acquisition of BioLife Solutions. The deal offers $11.25 in cash plus 0.1442 Repligen shares per BioLife share, pending approvals. The merger is subject to shareholder and regulatory approvals, with a special meeting scheduled for October 5, 2026. The exchange ratio is fixed, but the value of the share portion will fluctuate with Repligen's stock price.

stocktitan.net2 min

AUG 31

$IQVMedAI 8/10

Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment

Azenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.

finance.yahoo.com3 min

AUG 27

$RGENHighAI 8/10

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).

finance.yahoo.com2 min

AUG 25

$MRKHighAI 8/10

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

yahoo.com3 min

AUG 20